Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador
26.1.2021 14:00:00 EET | Business Wire | Press release
Aqua Lung, the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, today announced world-renowned wildlife photographer and conservationist Paul Nicklen is joining the brand as a global ocean ambassador. As part of the partnership, Nicklen will exclusively use Aqua Lung, Apeks, and O.ME.R. products during all dive expeditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005122/en/
Aqua Lung global ocean ambassador and SeaLegacy co-founder, Paul Nicklen with co-founder and President of SeaLegacy, Cristina Mittermeier. Photo credit: Joe Leahy
Nicklen, best-known for his incomparable underwater photography and ocean conservation efforts, will utilize the full range of industry-leading Aqua Lung, Apeks and O.ME.R. products from wetsuits, masks and fins to technical gear and regulators. Helping to grow the brand globally, Nicklen joins an elite roster of ambassadors at Aqua Lung including, Philippe Cousteau Jr., Ashlan Gorse Cousteau, and Greg Lecoeur.
“From day one, the Aqua Lung family has been kind and unwavering in their support of our mission to build community and restore the health and abundance of our oceans,” said Nicklen. “Personally, I love the simplicity and quality of the Aqua Lung products and I’m grateful the entire SeaLegacy team gets to use them. Most importantly, the products are reliable and give me the ability to focus on filming and being a photographer and conservationist.”
Paul Nicklen is a Canadian photographer and marine biologist specializing in the polar regions and their wildlife. Nicklen has completed more than 20 assignments for National Geographic and in 2014, co-founded SeaLegacy, a non-profit organization that propelled ocean conservation onto the world stage through the power of visual storytelling, impact campaigns and the funding of sustainability projects. In 2019, Nicklen was inducted into the International Photography Hall of and in that same year, was appointed to the Order of Canada.
“We are thrilled to welcome Paul Nicklen to the Aqua Lung family,” said Laurent Boury, Senior Vice President of Brands for the Aqua Lung Group. “Paul is an incredibly talented photographer and an important voice in ocean conservation, and we are honored that he chooses to use Aqua Lung, Apeks, and O.ME.R. products to further his work.”
Nicklen and the crew from SeaLegacy are slated to spend the next six months in the Bahamas, focusing on the development of an immersive content series to inspire and galvanize a global audience, shedding light on critical threats, tipping points, and scalable solutions unique to the region. Against the backdrop of Hurricane Dorian’s still ongoing recovery efforts and the ongoing Covid-19 pandemic, Nicklen and his team are documenting one of the most complex, yet promising, conservation stories as it unfolds. Using SeaLegacy’s storytelling expertise and Only One’s data-driven content delivery formula, this expedition will build a robust library of assets and supporting content that can be organized into actionable narratives and educational curriculum.
To learn more or to see Nicklen’s work, go to paulnicklen.com or follow him on Instagram. For more information about Aqua Lung products, visit AquaLung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005122/en/
Contact information
Lauren Schuil
lschuil@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
